Neurologic complications of antitumor antibody therapies

Antibody-based therapy is being explored across a variety of disease types. Several successes in oncology have become part of standard care for diseases such as colorectal cancer and non-Hodgkin's lymphoma. Traditional chemotherapeutic agents have had significant dose-limiting neurologic toxicities associated with their use. Although there are rare incidences of significant neurologic complications of antibody cancer therapy, these treatments are generally very well tolerated. Because most antibody therapy is adjunctive to other treatments, attribution to the immunologic component is often difficult to discern.